Obtained results showed that either genetic or pharmacological strategies may contribute to the reduction of albuminuria, glomerular hypertrophy, mesangial expansion, renal inflammation, and fibrosis induced by diabetes via regulation of MMP2, MMP9, and ADAM17 activities (Figure 8). Here, ADAM17 is linked to diabetes mellitus.